2. Academic Validation
  3. Treatment Approaches for Carbapenem-Resistant Acinetobacter baumannii Infections

Treatment Approaches for Carbapenem-Resistant Acinetobacter baumannii Infections

  • Drugs. 2025 Jan;85(1):21-40. doi: 10.1007/s40265-024-02104-6.
Alina Iovleva 1,  Vance G Fowler Jr 2 3,  Yohei Doi 4 5
Affiliations

Affiliations

  • 1 Center for Innovative Antimicrobial Therapy, Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
  • 2 Department of Medicine, Duke University School of Medicine, Durham, NC, USA.
  • 3 Duke Clinical Research Institute, Durham, NC, USA.
  • 4 Center for Innovative Antimicrobial Therapy, Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. [email protected].
  • 5 Departments of Microbiology and Infectious Diseases, Fujita Health University, Toyoake, Aichi, Japan. [email protected].
PMID: 39607595 DOI: 10.1007/s40265-024-02104-6
Abstract

Carbapenem-resistant Acinetobacter baumannii has been associated with over three hundred thousand annual deaths globally. It is resistant to most available Antibiotics and associated with high morbidity and mortality. No global consensus currently exists for treatment strategies that balance safety and efficacy because of heterogeneity of treatment regimens in current clinical practice and scarcity of large-scale controlled studies arising from difficulties in establishing robust clinical outcomes. This review outlines the epidemiology and resistance mechanisms of carbapenem-resistant A. baumannii, then summarizes available clinical data on each approved agent with activity against this pathogen. Emerging treatment options such as cefiderocol and sulbactam-durlobactam show promise, but their success hinges on comprehensive clinical validation and access in regions most impacted by this pathogen. New therapeutic modalities that are in various stages of clinical development are also discussed.

Figures
Products